These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 15153321)
1. CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme. Nygård JF; Sauer T; Nygård M; Skare GB; Thoresen SØ J Med Screen; 2004; 11(2):70-6. PubMed ID: 15153321 [TBL] [Abstract][Full Text] [Related]
2. CIN 2/3 and cervical cancer after an ASCUS pap smear. A 7-year, prospective study of the Norwegian population-based, coordinated screening program. Nygård JF; Sauer T; Skjeldestad FE; Skare GB; Thoresen SØ Acta Cytol; 2003; 47(6):991-1000. PubMed ID: 14674068 [TBL] [Abstract][Full Text] [Related]
3. Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program. Nygård JF; Nygård M; Skare GB; Thoresen SØ Cancer Causes Control; 2005 May; 16(4):463-74. PubMed ID: 15953989 [TBL] [Abstract][Full Text] [Related]
4. Cervical neoplasia in pap smears: risk of cervical intra-epithelial neoplasia (CIN) after negative or no prior smears in a population without a mass screening programme. Forsmo S; Jacobsen BK; Stalsberg H Int J Epidemiol; 1996 Feb; 25(1):53-8. PubMed ID: 8666505 [TBL] [Abstract][Full Text] [Related]
5. Incidence of cervical intraepithelial neoplasia grade III, and cancer of the cervix uteri following a negative Pap-smear in an opportunistic screening. Gram IT; Macaluso M; Stalsberg H Acta Obstet Gynecol Scand; 1998 Feb; 77(2):228-32. PubMed ID: 9512333 [TBL] [Abstract][Full Text] [Related]
6. Pap smear screening in women under 30 in the Norwegian Coordinated Cervical Cancer Screening Program, with a comparison of immediate biopsy vs Pap smear triage of moderate dysplasia. Nygård JF; Nygård M; Skare GB; Thoresen SO Acta Cytol; 2006; 50(3):295-302. PubMed ID: 16780024 [TBL] [Abstract][Full Text] [Related]
7. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. Nygård JF; Skare GB; Thoresen SØ J Med Screen; 2002; 9(2):86-91. PubMed ID: 12133929 [TBL] [Abstract][Full Text] [Related]
8. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less. Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308 [TBL] [Abstract][Full Text] [Related]
9. Smoking worsens the prognosis of mild abnormalities in cervical cytology. Guarisi R; Sarian LO; Hammes LS; Longatto-Filho A; Derchain SF; Roteli-Martins C; Naud P; Erzen M; Branca M; Tatti S; Costa S; Syrjänen S; Bragança JF; Syrjänen K Acta Obstet Gynecol Scand; 2009; 88(5):514-20. PubMed ID: 19308752 [TBL] [Abstract][Full Text] [Related]
10. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303 [TBL] [Abstract][Full Text] [Related]
11. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening. Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639 [TBL] [Abstract][Full Text] [Related]
12. Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy? Ferris DG; Wright TC; Litaker MS; Richart RM; Lorincz AT; Sun XW; Borgatta L; Buck H; Kramer L; Rubin R J Fam Pract; 1998 Feb; 46(2):125-34. PubMed ID: 9487318 [TBL] [Abstract][Full Text] [Related]
13. Risk factors, diagnosis and prognosis of cervical intraepithelial neoplasia among HIV-infected women. Lehtovirta P; Paavonen J; Heikinheimo O Int J STD AIDS; 2008 Jan; 19(1):37-41. PubMed ID: 18275645 [TBL] [Abstract][Full Text] [Related]
14. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study. Nygård M; Daltveit AK; Thoresen SO; Nygård JF BMC Health Serv Res; 2007 Jan; 7():10. PubMed ID: 17244348 [TBL] [Abstract][Full Text] [Related]
15. A mobile unit: an effective service for cervical cancer screening among rural Thai women. Swaddiwudhipong W; Chaovakiratipong C; Nguntra P; Mahasakpan P; Tatip Y; Boonmak C Int J Epidemiol; 1999 Feb; 28(1):35-9. PubMed ID: 10195661 [TBL] [Abstract][Full Text] [Related]
16. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S43-9. PubMed ID: 23519304 [TBL] [Abstract][Full Text] [Related]
17. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S56-63. PubMed ID: 23519306 [TBL] [Abstract][Full Text] [Related]
18. Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia. Liao SY; Stanbridge EJ Cancer; 2000 Mar; 88(5):1108-21. PubMed ID: 10699902 [TBL] [Abstract][Full Text] [Related]
19. High-grade cervical abnormalities and cervical cancer in women following a negative Pap smear with and without an endocervical component: a cohort study with 10 years of follow-up. Sultana F; English DR; Simpson JA; Canfell K; Gertig DM; Saville M Int J Cancer; 2014 Sep; 135(5):1213-9. PubMed ID: 24488882 [TBL] [Abstract][Full Text] [Related]
20. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]